Compare D R Horton Inc (DHI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs State Street SPDR S&P Biotech ETF — how do they compare? D R Horton Inc trades at $134.88 (market cap $37.99B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: D R Horton Inc is far larger — about 3.8× State Street SPDR S&P Biotech ETF's market cap, and D R Horton Inc pays a 1.33% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| DHI | XBI | |
|---|---|---|
Market Cap | $37.99B | $10.11B |
Volume | 2,974,460 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $167.78 | $169.55 |
52-Week Low | $132.53 | $104.99 |
Typical Hold Time | 46 Days | 38 Days |
Enterprise Value | $43.09B | — |
Dividend Yield | 1.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) trades at $135.82, up 1.91% today, but faces a bearish technical outlook with resistance at $137. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Revenue declined to $34.25B in 2025, and net income margin compressed to 9.15%. Analysts maintain a buy consensus with a $156.57 target, but rising mortgage rates and housing market weakness pose headwinds.
The stock offers value with a P/E of 12.95 and strong cash flow, but investor sentiment is cautious due to macroeconomic risks. Near-term performance hinges on Q3 earnings and interest rate trends. The current price near the low end of the target range suggests limited downside if fundamentals hold.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
